Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Stutterheim, Janine; Gerritsen, Annemieke; Zappeij-Kannegieter, Lily; YALÇIN, BİLGEHAN; Dee, Rob; van Noesel, Max; Berthold, Frank; Versteeg, Rogier; Caron, Huib; van der Schoot, C.; Tytgat, Godelieve

doi:10.1373/clinchem.2008.117945

Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., YALÇIN B., Dee R., van Noesel M. M., ...Daha Fazla

CLINICAL CHEMISTRY, cilt.55, sa.7, ss.1316-1326, 2009 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 55 Sayı: 7
Basım Tarihi: 2009
Doi Numarası: 10.1373/clinchem.2008.117945
Dergi Adı: CLINICAL CHEMISTRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1316-1326
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity.